Dividend stocks are everywhere, but many just downright stink. In some cases, the business model is in serious jeopardy, or the dividend itself isn't sustainable. In others, the dividend is so low, it's not even worth the paper your dividend check is printed on. A�solid dividend�strikes the right balance of growth, value, and sustainability.
Today, and one day each week for the rest of the year, we're going to look at one dividend-paying company that you can put in your portfolio for the long term without too much concern. This isn't to say that these stocks don't share the same macro risks that other companies have, but they are a step above your common grade of dividend stock. Check out�last week's selection.
This week, I'll point out a "purrrrfectly" positioned company in the pet sector, Zoetis (NYSE: ZTS ) , and highlight why it could be paying hefty dividends for decades.
KMG Chemicals, Inc., incorporated on July 30, 1992, manufactures, formulates and globally distributes specialty chemicals. The Company has acquired and operates businesses selling electronic chemicals and industrial wood treating chemicals. The Company operates in two segments: electronic chemicals and wood treating chemicals. The Company's electronic chemicals segment provides wet process chemicals to the semiconductor industry, primarily to clean and etch silicon wafers in the production of semiconductors. The Company supplies wet process chemicals to the semiconductor industry in the United States and Europe. Its wood treating chemicals, pentachlorophenol (penta), and creosote, are sold to industrial customers who use these preservatives primarily to extend the useful life of utility poles and railroad crossties. The Company is the supplier of penta in North America, and supplier of creosote in the United States to wood treaters who do not produce their own creosote. On March 1, 2012, the Company discontinued its animal health business. In June 2013, the Company announced that it completed the acquisition of the Ultra Pure Chemicals subsidiaries of OM Group Inc located in the United States, England and Singapore.
Electronic Chemicals
The Company's electronic chemicals business sells wet process chemicals primarily to the semiconductor industry. These chemicals are used to clean and etch silicon wafers in the production of semiconductors. The Company's products include sulfuric, phosphoric, nitric and hydrofluoric acids, ammonium hydroxide, hydrogen peroxide, isopropyl alcohol and various blends of chemicals. The Company's products are sold in bulk and in containers, including bottles, drums and totes. This process is accomplished at the Company's Pueblo, Colorado, Hollister, California and Milan, Italy facilities, although the Company contracts with General Chemical to produce certain products for the Company at its facility. As of July 31, 2012, the Company's electronic ! chemicals business accounted for 58.5% of its net sales.
Wood Treating Chemicals
The Company supplies penta and creosote to industrial customers who use these products to extend the useful life of wood, primarily utility poles and railroad crossties. The Company's penta products include penta blocks, solutions and hydrochloric acid, a byproduct of penta production. Penta is used primarily to treat utility poles, protecting them from insect damage and decay. The Company manufactures solid penta blocks at its facility in Matamoros, Mexico. The Company sells solid penta to its customers, or make it into a liquid solution of penta concentrate at its Matamoros, Mexico and Tuscaloosa, Alabama facilities. The Company sells penta products primarily in the southeastern and northwestern United States and in Canada. The hydrochloric acid the Company produces as a byproduct of penta production is sold in Mexico for use in the steel and oils well service industries. Creosote is a wood preservative used to treat utility poles and railroad crossties. Creosote is produced by the distillation of coal tar, a by-product of the transformation of coal into coke. The Company sells creosote to wood treaters throughout the United States. As of July 31, 2012, the Company's wood treating chemicals constituted about 41.4% of the Company's net sales.
The Company competes with Honeywell, Kanto Corporation, Avantor, BASF and the OM Group.
Advisors' Opinion: - [By Monica Gerson]
Analysts expect KMG Chemicals (NYSE: KMG) to report its Q4 earnings at $0.27 per share on revenue of $79.00 million. KMG Chemicals shares surged 4.99% to close at $23.76 on Friday.
- [By Monica Gerson]
KMG Chemicals (NYSE: KMG) is expected to report its Q4 earnings at $0.27 per share on revenue of $79.00 million.
Brown & Brown (NYSE: BRO) is projected to post its Q3 earnings at $0.40 per share on revenue of $348.85 million.
- [By Seth Jayson]
KMG Chemicals (NYSE: KMG ) reported earnings on June 10. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended April 30 (Q3), KMG Chemicals beat expectations on revenues and beat expectations on earnings per share.
Top 10 Long Term Companies To Buy For 2014: Myriad Genetics Inc (MYGN)
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).
As of June 30, 2012, the Company had launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.
Molecular Diagnostic Tests
The Company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recurrence and measure a patient's exposure to drug therapy to ensu! re optimal dosing and reduced drug toxicity. The Company's BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company's total revenue during the fiscal year ended June 30, 2012. Its The Company's COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person's risk of developing colorectal cancer or uterine cancer.
The Company's COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company's MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company's OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company's PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. The Company's PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.
The Company's Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company's TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.
Companion Diagnostic Services and Other Revenue
! Through M! yriad RBM Inc., the Company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical researches industries utilizing its multiplexed immunoassay technology. The Company's technology enables the Company to screen large sets of clinical samples from both diseased and non-diseased populations against the Company's menu of biomarkers. The Company's companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture.
The Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeutic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company's internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.
Advisors' Opinion: - [By John Udovich]
On Tuesday, small cap cancer diagnostic stock Myriad Genetics, Inc (NASDAQ: MYGN) jumped 11.42% in one day, meaning its worth taking a closer look at the stock along with the performance of small cap cancer diagnostic stocks like Rosetta Genomics Ltd (NASDAQ: ROSG) and�Genomic Health, Inc (NASDAQ: GHDX) plus mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX). I should mention that we have had�Myriad Genetics in our SmallCap Network Elite Opportunity (SCN EO) portfolio since February 5th and we are already up 18.50%���a nice return in just two weeks time.
- [By John Kell]
Myriad Genetics Inc.(MYGN) said it has agreed to acquire Crescendo Bioscience Inc. for $270 million in cash as the biopharmaceutical company looks to expand into the high-growth autoimmune market. Shares climbed 12% to $30.35 premarket.
Top 10 Long Term Companies To Buy For 2014: Panera Bread Company(PNRA)
Panera Bread Company, together with its subsidiaries, owns, operates, and franchises retail bakery-cafes in the United States and Canada. Its bakery-cafes offer fresh baked goods, sandwiches, soups, salads, custom roasted coffees, and other complementary products, as well as provide catering services. The company also manufactures and supplies dough and other products to company-owned and franchise-operated bakery-cafes. As of March 29, 2011, it owned and franchised 1,467 bakery-cafes under the Panera Bread, Saint Louis Bread Co., and Paradise Bakery & Cafe names. The company was founded in 1981 and is based in St. Louis, Missouri.
Advisors' Opinion: - [By James O'Toole]
Panera Bread (PNRA) is the latest chain to introduce automated service, announcing last month that it plans to bring self-service ordering kiosks as well as a mobile ordering option to all its locations within the next three years. The news follows moves from Chili's and Applebee's to place tablets on their tables, allowing diners to order and pay without interacting with human wait staff at all.
- [By WALLSTCHEATSHEET]
Now that Panera has become a mainstream American brand with millions of loyal customers that enjoy one of the most casual and comfortable atmospheres available,��it�� a long-term OUTPERFORM. However, a tentative consumer, a somewhat poor valuation, and an artificially-inflated stock market are reasons�for caution.
- [By Steve Symington]
And for those of you keeping track, that 5.5% growth also shows a marked improvement over the last quarter's paltry 1% comparable restaurant sales increase, and even beats the pants off of Panera Bread Company's (NASDAQ: PNRA ) respectable 3.3% comp-sales growth in Q1.
- [By Ben Levisohn]
The main risk for Chipotle, Kalinowski says, is “a relatively high valuation compared to most other restaurant stocks we cover.” Chipotle trades at 36.73 times forward earnings, while Starbucks (SBUX) trades at 24.7 times, Panera Bread (PNRA) trades at 19.1 times and McDonald’s (MCD) trades at 15.8 times.
Top 10 Long Term Companies To Buy For 2014: Host Hotels & Resorts Inc (HST)
Host Hotels & Resorts, Inc (Host Inc), incorporated on September 28, 1998 operates as a self-managed and self-administered REIT. Host Inc. owns properties and conducts operations through Host Hotels & Resorts, L.P. (Host L.P.) of which Host Inc. is the sole general partner and in which it holds approximately 98.6% of the partnership interests (OP units) as of December 31, 2012. As of February 25, 2013, the Company had 118 primarily luxury and upper-upscale hotels containing approximately 62,600 rooms, with the majority located in the United States of America, and 15 properties located outside of the United States of America, in Canada, New Zealand, Chile, Australia, Mexico and Brazil. In addition, the Company owns non-controlling interests in two international joint ventures: a joint venture in Europe, which owns 19 luxury and upper upscale hotels with approximately 6,100 rooms in France, Italy, Spain, The Netherlands, the United Kingdom, Belgium, Poland and Germany; and a joint venture in Asia/Pacific, which owns one hotel in Australia and minority interests in two operating hotels in India and five additional hotels in India under development. In June 2013, the Company announced that it acquired the fee-simple interest in the 426-room Hyatt Place Waikiki Beach in Honolulu. In July 2013, the Company sold the 336-room Ritz-Carlton, San Francisco to an investment vehicle sponsored by Thayer Lodging Group. In January 2014, Host Hotels & Resorts Inc sold an 89% interest in the entity that owns the Philadelphia Marriott Downtown (the Hotel).
The Company's other real estate joint ventures include the development of a 225-room Hyatt Place in Nashville, Tennessee, and the development of a 131-unit vacation ownership project in Maui, Hawaii adjacent to the Company's Hyatt Regency Maui Resort & Spa. The Company has 118 hotels in its portfolio, primarily consisting of luxury and upper upscale properties. These properties typically include meeting and banquet facilities, a variety of restaurants and! lounges, swimming pools, exercise facilities and spas, gift shops and parking facilities.
Advisors' Opinion: - [By Diane Alter]
Dividend Stocks That Increased Payout in September
Accenture plc (NYSE: ACN) announced a 14.8%, or $0.12 per share, increase to its semiannual dividend. The management consulting firm will now pay a semiannual dividend of $0.93. Shares yield 2.53%. Agruim Inc. (NYSE: AGU) boosted its dividend by $1.00 per share to a total dividend of $3.00 on an annualized basis. Shares of the global retailer of agricultural products now sprout a 3.54% yield. Air Industries Group Inc. (NYSE: AIRI) doubled its dividend to $0.125 per share. The maker of airplane and helicopter parts now floats a lofty yield of 6.6%. Alexandria Real Estate Equities Inc. (NYSE: ARE) upped its dividend 4.6% to $0.68 per quarter for a yield of 4.21%. Banner Corp. (Nasdaq: BANR) boosted its quarterly dividend 25% to $0.15 per share. The parent company of Banner and Islander Bank serves the Pacific Northwest region. Brady Corp. (NYSE: BRC) lifted its quarterly dividend 2.6% to $0.78 per share. It was the 28th straight dividend increase from the identification solutions company. Shares yield 2.57%. Campbell Soup Co. (NSE: CPB) raised its quarterly dividend to $0.31 per share, up from $0.29. The company last raised its dividend in November 2010. Shares yield a hearty 3.06%. CLARCOR Inc. (NYSE: CLC) raised its quarterly dividend 26% to $0.17 per share. It's the largest percentage increase from the Tennessee-based diversified marketer of mobile filtration and packaging products in the last 20 years, and it continues the company's consecutive streak of increasing dividends for the last 30 years. Franklin Resources Inc. (NYSE: BEN) boosted its quarterly dividend 2.6% to $0.10 per share. Frisch's Restaurants Inc. (NYSE: FRS) increased its quarterly dividend 12.5% to $0.18. Shares yield 3.10% The Goodyear Tire & Rubber Company (NYSE: GT), in a move that suggests good times are ahead, reinstated its dividend at $0.05 per share. Good - [By Michael Flannelly]
Host Hotels and Resorts Inc (HST) announced early on Monday that it is raising its quarterly dividend payout from 11 cents per share to 12 cents per share, a 9.1% increase.
This quarterly dividend payout will be paid on October 15 to shareholders of record on September 30, with an ex-dividend date of September 26.
Host Hotels shares were inactive during pre-market trading on Monday. The stock is up 15.25% year-to-date.
- [By alicet236]
Host Hotels & Resorts Inc. (HST): President and CEO W. Edward Walter Sold 200,000 Shares
President and CEO of Host Hotels & Resorts Inc. (HST) W. Edward Walter sold 200,000 shares on 05/06/2014 at an average price of $21.31. Host Hotels & Resorts Inc. is a Maryland corporation that operates as a self-managed and self-administered real estate investment trust, or REIT. Host Hotels & Resorts Inc. has a market cap of $16.22 billion; its shares were traded at around $21.43 with a P/E ratio of 49.50 and P/S ratio of 3.09. The dividend yield of Host Hotels & Resorts Inc. stocks is 2.33%. Host Hotels & Resorts In.c had an annual average earnings growth of 7.0% over the past five years.
- [By Dimitra DeFotis]
Apartment Invest & Management (AIV)
Ameriprise (AMP)
Edison International (EIX)
Host Hotels & Resorts (HST)
Kimco Realty (KIM)
Kroger (KR)
Lincoln National (LNC)
Newfield Exploration (NFX)
Republic Services (RSG)
UnitedHealth (UNH)
Verizon (VZ)
Wells Fargo (WFC)
WellPoint (WLP)
Wyndham Worldwide (WYN)
Xcel Energy Utilities (XEL)
Top 10 Long Term Companies To Buy For 2014: PureSafe Water Systems Inc (PSWS)
PureSafe Water Systems, Inc., incorporated on March 9, 1987, is engaged in the design and development of its technology to be used in the manufacture and sale of water purification systems both in and outside the United States. The Company�� PureSafe First Response Water System (PureSafe FRWS) is self-contained and purifies most types of contaminated fresh or service water, including seawater that may be found at a first response emergency site. This system is mobile, by helicopter or transported by truck.
The PureSafe FRWS utilizes its technology which consists of water extraction boom that extracts water from the ocean, streams, ponds, pools of floodwater or a failed municipal distribution system. The extracted water is then treated by the application of advanced water treatment technologies which employ multiple stage filtration, multiple stage sanitation (including ozone, chlorine and ultraviolet purification techniques), reverse osmosis membranes, mineralization and final polishing to meet the standard drinking water requirements of the United States Environmental Protection Agency (the EPA). Its 2nd prototype (FRWS unit) unit can produce EPA compliant drinking from contaminated fresh or surface water at the rate of 30,000 gallons per day, to provide drinking water to 45,000 people. The unit has a built in generator and water bagging capability at the rate of 30,000 and a half liters bags of water per day
The Company competes with GE, Siemens, Severn Trent, Ecospheres Technology, Lenntech, Testa/Viwa, Lifekeeper, Mobile MaxPure, Bi Pure Water, Rodi, Global Water Group, Nirosoft, LifeStream, and Aquapura Tempest.
Advisors' Opinion: - [By John Udovich]
Small cap Sodastream International Ltd (NASDAQ: SODA), an Israeli based developer, manufacturer and marketer of�home beverage carbonation systems, has attracted its share of hype over both its products and its stock, but could other small cap water stocks like Primo Water Corporation (NASDAQ: PRMW), Puresafe Water Systems Inc (OTCMKTS: PSWS) and Alkaline Water Company Inc (OTCBB: WTER) attract a similar following? After all, Sodastream International has managed to create a significant amount of buzz from consumers, investors and even short sellers because it�� the�world's largest manufacturer, distributor and marketer of home carbonation systems as its�brands are sold in over 60,000 retail stores in 45 countries. Sodastream International is also up 45.7% since the start of the year, up 70.2% over the past year and up 99.3% since November 2010, but shares did spike up to the $75 level in the middle of 2011 and now trade at the $63 level.
Top 10 Long Term Companies To Buy For 2014: Fiat SpA (FIATY)
Fiat SpA, incorporated in 1906, is engaged principally in the manufacture and sale of automobiles, agricultural and construction equipment and commercial vehicles. It also manufactures other products and systems, principally engines, transmission systems, automotive-related components, metallurgical products and production systems. In addition, it is involved in certain other sectors, including publishing and communications. The Company and its subsidiaries operates approximately in 50 countries. The Company operates under five segments: automobiles, agricultural and construction equipment (CNH-Case New Holland), trucks and commercial vehicles, components and production systems, and other businesses. On 10 June 2009, the Company acquired 20% interest in Chrysler Group LLC. In January 2014, Fiat SpA announced that through its wholly owned subsidiary Fiat North America LLC (FNA) completed its announced acquisition of all of the VEBA Trust�� membership interests in Chrysler Group LLC.
Automobiles
The Company�� automobiles segment designs, develops and sells automobiles, which include Fiat, Alfa Romeo, Lancia, Abarth, Fiat Professional, Maserati and Ferrari. During the year ended December 31, 2009, this segment delivered a total of 2,150,700 passenger cars and light commercial vehicles.
Agricultural and Construction Equipment (CNH-Case New Holland)
The Company�� agricultural and construction equipment segment is engaged in the development of the agricultural and construction equipment industries in Europe and the United States. CNH operates through six brands: Case IH, New Holland Agriculture, Steyr, New Holland Construction, Case Construction and Kobelo. Case IH includes a range of tractors, combines and bailers. New Holland Agriculture�� products include tractors, harvesting equipment and telehandlers. Steyr is the producer of tractors in Austria. New Holland Construction is a producer of construction equipment with a network of 800 dealers an! d more than 2,100 points of sale in 100 countries.
Case Construction sells and provides service support for a range of construction machinery: from loader backhoes to crawler and wheel excavators, from wheel loaders to wheel and crawler skid steer loaders, from articulated dumpers to telescopic handlers. Kobelco produces and sells a range of compact, mid-size and full-size excavators ranging from 1.9 to 88 tons. It owns more than 250 sales outlets located throughout North America.
Truck and Commercial Vehicles
Truck and Commercial Vehicles segment develops, produces and sells a range of trucks and buses under the brands, which include Iveco, Iveco Irisbus, Iveco Astra and Iveco Magirus. Iveco produces a range of light, medium and heavy commercial and industrial vehicles for transportation and distribution of goods. Iveco Irisbus offers a range of vehicles, from minibuses to touring coaches, from urban buses to interurban buses designed to provide a solution to a variety of transportation needs, whether intraurban or interurban.
Iveco Astra produces 2, 3 and 4-axle vehicles for mining and offers over 210 Extra Heavy-Duty models for dump bodies, water and fuel tanks, cement mixers and pumps, drills, mobile service. In addition, it provides rigid dumpers of 14, 28, 32 and 40 tons and articulated dumpers of 25, 30, 35 and 40 tons. Iveco Magirus offers s range of vehicles for situations like fire, floods, earthquakes and explosions. It offers them under the Iveco Magirus, Lohr Magirus, Iveco Special Vehicles and Camiva brands.
Components and Production Systems
The Company�� products under the Components and Production Systems include FPT Powertrain Technologies, Magneti Marelli, Teksid and Comau. FPT Powertrain Technologies provides engines and transmissions. Magneti Marelli designs and produces automotive systems and components: from lighting to engine control systems, from suspensions to electronic systems, from exhaust system! s to comp! onents to the aftermarket and motorsport. Teksid is the producer of grey and nodular iron castings. It manufactures approximately 600 thousand tons of engine blocks, cylinder heads, engine components, transmissions parts, gearboxes and suspensions. Comau makes body welding and assembly robots, and machining and assembly for mechanical systems. It delivers turnkey solution, which includes design, production, installation, production startup and maintenance to the customers.
Other Businesses
The Company�� other businesses includes the contribution from the Company�� publishing businesses, service companies and holding companies.
Advisors' Opinion: - [By WWW.DAILYFINANCE.COM]
Does the dealer lose money on recalls? Generally, no.
Labor rates vary by dealer, but at $100 per hour, that would be $150, with another $89.68 for parts, he said, for a total $240. Dealers make a profit on the parts and technician labor, and the work helps pay for other service staff and overhead, Huffines said by email. A service manager at Raymond Chevrolet put the total cost of a Cobalt recall fix from his lot at $260 for GM. GM said the repair took 90 minutes and declined to comment on the cost. Huffines concluded, "Does the dealer lose money on recalls? Generally, no. Does the dealer make a very nice profit on recalls? Generally, no." The biggest cost to GM, Huffines said, was car rentals offered to ignition switch recall customers, which could be $1,000 to $2,500. GM said 83,000 cars had been loaned to customers. Dealers with their own fleets of service cars love the loaner car option. Mike Bowsher, co-chairman of the GM Dealers Executive Board and president of the Carl Black Automotive Group, based in the Atlanta area, said his four stores sold 10 cars in one week to people who came in for recall repairs. Some bought the loaner cars. Meanwhile, his parts and service business has set records three months running, thanks to the chance to upsell customers who might otherwise bypass the dealership for repair work. "I would have never had a shot at that," he said. Recalls, the 'New Normal' A massive recall by Toyota (TM) in 2009 and 2010 had an immediate effect on the Japanese automaker's U.S. sales, in contrast to GM this year. GM's recalls have come at a time when the economy is healthier, and the company has benefited from the fact that the recalls linked to fatalities are from discontinued models, said Kelley Blue Book senior analyst Karl Brauer. There may be a bigger issue, as well: recalls have become commonplace for almost every automaker, turning into "white noise" for consumer, say analysts and dealers alike. Ray Scarpelli said that with - [By Jim Woods]
It’s impressive for Ford, and for Ford stock going forward, that the company continues to best rivals�General Motors�(GM) and�Fiat���(FIATY)�Chrysler�in the pickup wars. You would think that, after outselling the competition over the past three decades, there would be at least a small bump in the road for the line of iconic Ford pickups. But if you thought that you�� be wrong.
Top 10 Long Term Companies To Buy For 2014: Antares Pharma Inc (ATRS)
Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company�� subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices.
In the gel-based area, it received Food and Drug Administration (FDA) approval in December 2011 for its oxybutynin gel 3% product, Anturol, for the treatment of overactive bladder. Antares also has a licensing agreement with Watson Watson Pharmaceuticals, Inc. (Watson) under which Watson will commercialize its topical oxybutynin gel 3% product in the United States and Canada. Its gel portfolio also includes Elestrin (estradiol gel) in the United States for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies.
Pressure Assisted Injection Devices
The Company�� Pressure Assisted Injection Devices consists of three products: reusable needle-free injectors, disposable pressure assisted auto injectors and disposable pen injectors. Reusable needle-free injectors deliver precise medication doses through high-speed, pressurized liquid penetration of the skin without a needle. The injector employs a disposable pl! astic needle-free syringe, which offers liquid medication delivery through an opening that is approximately half the diameter of a standard, 30-gauge needle.
Disposable pressure assisted auto injectors is a technology of controlled pressure delivery of drugs into the body utilizing a spring power source. The Vibex is designed to provide fast subcutaneous or intramuscular injections of up to 0.5ml with minimal discomfort and improved convenience in conjunction with the enhanced safety of a shielded needle. Disposable pen injectors are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. The devices contain mechanisms that specify the dose to be delivered by defining the amount of movement by the stopper in the cartridge with each device actuation.
The Vision/Tjet has been sold for use in more than 30 countries to deliver either insulin or hGH. The product features a reusable, spring-based power source and disposable needle-free syringe, which acts as the pathway for the injectable drug through the skin and allows for viewing of the medication dose prior to injection. The product is also reusable, with each device designed to last for approximately 3,000 injections (or approximately two years) while the needle-free syringe, when used with insulin or hGH, is disposable after approximately one week when used by a single patient for injecting from multi-dose vials. The Vision/Tjet administers injectables by using a spring to push the active ingredient in solution or suspension through a micro-fine opening in the needle-free syringe. The opening is approximately half the diameter of a 30-gauge needle. The Vision/Tjet is primarily used in the United States, Europe, Asia and Japan.
Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies. Its Vibex disposable product combines a low-energy, spr! ing-based! power source with a hidden needle, which delivers up to 0.5ml of the needed drug solution subcutaneously or intramuscularly. Antares is also developing a Vibex MTX auto injector for delivery of methotrexate for treatment of rheumatoid arthritis. The Company�� multi use, disposable pen injector complements its portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi- dose cartridges. The disposable pen is in the stage of development where devices are being used in clinical evaluations.
Transdermal Products
The Company�� ATD system penetrates the skin to deliver a variety of treatments. The gels consist of a hydro-alcoholic base, including a combination of permeation enhancers. Products being developed/ commercialized include Anturol, Elestrin and Nestragel. Elestrin is a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Its other injectable drugs that are presently self-administered and may be suitable for injection with its systems include therapies for the prevention of blood clots and treatments for multiple sclerosis, migraine headaches, inflammatory diseases, impotence, infertility, acquired immune deficiency symdrome (AIDS) and hepatitis.
The Company competes with Ypsomed AG, SHL Group AB, OwenMumford Ltd., West Pharmaceuticals, Becton Dickinson, Haselmeir GmbH, Elcam Medical, Vetter Pharma, Bioject Medical Technologies Inc., The Medical House PLC, Watson, Abbott, Eli Lilly, Auxillium, Inc., Endo Pharmaceuticals, Teva, Mylan, Roxane, Bedford Labs, APP Pharmaceuticals, Hospira, Pfizer, GSK/Astellas, Warner Chilcott and Allergan.
Advisors' Opinion: - [By Keith Speights]
1. Antares Pharma (NASDAQ: ATRS )
Antares has experienced a roller-coaster ride so far this year. The stock was up more than 10% early in January, then proceeded to fall by more than 20% by late February. Since then, Antares has clawed its way back and now stands up a little over 10% for the year.�
- [By Monica Gerson]
Antares Pharma (NASDAQ: ATRS) shares tumbled 3.09% to touch a new 52-week low of $3.14. Antares Pharma's PEG ratio is -0.29.
eGain (NASDAQ: EGAN) shares fell 3.76% to reach a new 52-week low of $6.40. eGain's trailing-twelve-month ROE is -8.92%
- [By Luke Jacobi]
Antares Pharma (NASDAQ: ATRS) added 6.65 percent to close at $4.33 following the announcement that an FDA decision is expected on its drug on October 14. Equities
- [By Keith Speights]
Antares Pharma (NASDAQ: ATRS ) announced its first-quarter results �Wednesday morning but failed to impress the market. Shares were down around 3% in midday trading. Here are the highlights from the company's results.
